Pattern analysis of microtubule-polymerizing and -depolymerizing agent combinations as cancer chemotherapies

International Journal of Oncology

Volumn 31, Issue 6, 2007, Pages 1281-1291

  Uppal, S O ^a   Li, Y ^a   Wendt, E ^a   Cayer, M L ^a   Barnes, J ^a   Conway, D ^a   Boudreau, N ^a   Heckman, C A ^a  

^a BOWLING GREEN STATE UNIVERSITY   (United States)

Author keywords

Drug resistance; Filopodia; PAK dependent protrusions; Quantitative shape; Ruffling; Tubulin binding compounds

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE; PACLITAXEL; TUBULIN MODULATOR;

ANIMAL; ARTICLE; CELL CYCLE; CLINICAL TRIAL; DRUG EFFECT; HUMAN; METABOLISM; MICROTUBULE; MITOSIS; NEOPLASM; PATHOLOGY; PHENOTYPE; RAT; RAT STRAIN;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CLINICAL TRIALS AS TOPIC; COLCHICINE; HUMANS; MICROTUBULES; MITOSIS; NEOPLASMS; PACLITAXEL; PHENOTYPE; RATS; RATS, INBRED STRAINS; TUBULIN MODULATORS;

EID: 38449085825     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.6.1281     Document Type: Article

References (91)

1. Zhou J, Panda D, Landen JW, Wilson L and Joshi HC: Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem 277: 17200-17208, 2002. (Pubitemid 34967753)
2. Blajeski AL, Phan VA, Kottke TJ and Kaufmann SH: G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest 110: 91-99, 2002.
3. Chen JG, Yang CPH, Cammer M and Horwitz SB: Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 63: 7891-7899, 2003.
4. Isbrucker RA, Cummins J, Pomponi SA, Longley RE and Wright AE: Tubulin polymerizing activity of dictyostatin-1, a polyketide of marine sponge origin. Biochem Pharmacol 66: 75-82, 2003.
5. Yvon A-MC, Wadsworth P and Jordan MA: Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10: 947-959, 1999. (Pubitemid 29193723)
6. Elnakady YA, Sasse F, Lunsdorf H and Reichenbach H: Disorazol A(1), a highly effective antimitotic agent acting on tubulin polymerization and inducing apoptosis in mammalian cells. Biochem Pharmacol 67: 927-935, 2004. (Pubitemid 38201638)
7. Garcia P, Braguer D, Caries G and Briand C: Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses. Anticancer Drugs 6: 533-544, 1996.
8. Giannakakou P, Robey R, Fojo T and Blagosklonny MV: Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncology 20: 3806-3813, 2001.
9. Valiron O, Caudron N and Job D: Microtubule dynamics. Cell Mol Life Sci 58: 2069-2084, 2001.
10. Mitchison T and Kirschner M: Microtubule assembly nucleated by isolated centrosomes. Nature 312: 232-237, 1984.
11. Mollinedo F and Gajate C: Microtubule, microtubule-interfering agents and apoptosis. Apoptosis 8: 413-450, 2003.
12. Derry WB, Wilson L and Jordan MA: Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 34: 2203-2211, 1995.
13. Dhamodharan RI, Jordan MA, Thrower D, Wilson L and Wadsworth P: Vinblastine suppresses dynamics of individual microtubules in living cells. Mol Biol Cell 6: 1215-1229, 1995.
14. Hayden JH, Bowser SS and Rieder CL: Kinetochores capture astral microtubules during chromosome attachment to the mitotic spindle: direct visualization in live newt lung cells. J Cell Biol 111: 1039-1045, 1990.
15. Wilson L and Farrell KW: Kinetics and steady state dynamics of tubulin addition and loss at opposite microtubule ends: the mechanism of action of colchicine. Ann NY Acad Sci 466: 690-708, 1986.
16. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980.
17. Pellegrini F and Budman DR: Tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 23: 264-273, 2005. (Pubitemid 40770744)
18. Jordan MA and Wilson L: Microtubule as a target for anticancer drugs. Nat Rev Cancer 4: 253-265, 2004.
19. David-Pfeuty T, Simon C and Pantaloni D: Effect of antimitotic drugs on tubulin GTPase activity and self-assembly. J Biol Chem 254: 11696-11702, 1979. (Pubitemid 10140091)
20. Bruno R, Hille D, Riva A, Vivier N, Huinnink WWTB, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravclin PM and Sheiner LB: Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187-196, 1998. (Pubitemid 28041598)
21. Baker SD, Zhao M, Lee CKK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A and Carducci MA: Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 10: 1976-1983, 2004.
22. Heckman CA, Campbell AE and Wetzel B: Characteristic shape and surface changes in epithelial transformation. Exp Cell Res 169: 127-148, 1987.
23. Heckman CA: Geometrical constraints on the shape of cultured cells. Cytometry 11: 771-783, 1990.
24. Heckman CA and Plummer HK III: A prospective assay for antipromoter effects in epithelial cells. Anticancer Res 12: 1915-1916, 1992.
25. Heckman CA, Oravecz KI, Schwab D and Pontén J: Ruffling and locomotion: role in cell resistance to growth factor-induced proliferation. J Cell Physiol 154: 554-565, 1993. (Pubitemid 23076324)
26. Heckman CA, Plummer HK III and Runyeon CS: Persistent effects of phorbol 12-myristate 13-acetate: Possible implication of vesicle traffic. J Cell Physiol 166: 217-230, 1996.
27. Heckman CA and Jamasbi RJ: Describing shape dynamics in transformed rat cells through latent factors. Exp Cell Res 246: 69-82, 1999.
28. Heckman CA, Plummer HK III and Mukherjee R: Enhancement of the transformed shape phenotype by microtubule inhibitors and reversal by an inhibitor combination. Int J Oncol 16: 700-723, 2000.
29. Georgoulias V, Kourousis C, Androulakis N, Kakolyris S, Papadakis E, Bouros D, Apostolopoulou F, Georgopoulou T, Agelidou M, Souglakos J, Halkaldakis G and Hatzidakl D: Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer. Semin Oncol 24 (suppl 14): 9-14, 1997.
30. Ellis GK, Gralow JR, Pierce HI, Williams MA and Livingston RB: Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: High complete response rate in a phase I-II study of doxorubicin-treated patients. J Clin Oncol 17: 1407-1412, 1999.
31. Cocconi G, Mambrini A, Quarta M, Vasini G, Bella MA, Ferrozzi F and Beretta MD: Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma. Cancer 88: 2731-2738, 2000. (Pubitemid 30417933)
32. Cohen RB, Mueller SC, Haden K and deSouza P: Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer. Cancer Invest 18: 422-428, 2000.
33. Miller VA, Krug LM, Ng KK, Pizzo B, Perez W, Heelan RT and Kris MG: Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 18: 1346-1350, 2000. (Pubitemid 30159855)
34. Kornek GV, Ulrich-Pur H, Penz M, Haider K, Kwasny W, Depisch D, Kovals E, Lang F, Schneeweiss B and Scheithauer W: Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 19: 621-627, 2001.
35. Leu KM, Kim K, Larson M, Larson M and Schiller JH: Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. Lung Cancer 34: 105-113, 2001.
36. Marti JL, Bueso P, Mayordomo JI, Isla MD, Saenz A, Escudero P, Murillo L, Filipovich E, Andres R and Tres A: Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines. Ann Oncol 12: 1061-1065, 2001. (Pubitemid 32834485)
37. Pectasides D, Dimopoulos MA, Aravantinos G, Kalophonos HP, Papacostas P, Briasoulis E, Cogas E, Papadimitriou C, Skarlos D, Kosmidis P and Fountzilas G: First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study. Anticancer Res 21: 3575-3580, 2001. (Pubitemid 34224267)
38. Andres R, Mayordomo JI, Isla D, Marti JL, Escudero P, Filipovich E, Saenz A, Alvarez I, Polo E and Tres A: Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy. Br J Cancer 86: 1017-1018, 2002. (Pubitemid 34272293)
39. Ginopoulos P, Kontomanolis E, Kardamakis D, Sougleri M, Rathosis S, Karana A, Christias H and Mandellos G: A phase II study of non-platinum based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer. Lung Cancer 38: 199-203, 2002. (Pubitemid 35157756)
40. Rodríguez J, Calvo E, Cortes J, Santisteban M, Perez-Calvo J, Martinez-Monge R, Brugarolas A and Fernandez-Hidalgo Ó: Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: A phase II study. Breast Cancer Res Treat 76: 47-56, 2002.
41. Sanchez JM, Balana C, Font A, Sanchez JJ, Manzano JL, Guillot M, Margeli M, Richardet M and Rosell R: Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Lung Cancer 38: 309-315, 2002.
42. Airoldi M, Cattel L, Marchionatti S, Recalenda V, Pedani F, Tagini V, Bumma C, Beatrice F, Succo G and Gabriele AM: Docetaxel and vinorelbine in recurrent head and neck cancer. Am J Clin Oncol Cancer Clin Trials 26: 378-381, 2003.
43. Airoldi M, Cattel L, Pedani F, Marchionatti S, Tagini V, Bumma C and Recalenda V: Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. Acta Oncol 42: 186-194, 2003.
44. Aravantinos G, Bafaloukos D, Fountzilas G, Christodoulou C, Papadimitriou C, Pavlidis N, Kalofonos HP, Gogas H, Kosmidis P and Dimopoulos MA: Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol 14: 1094-1099, 2003.
45. Gómez-Bernal A, Cruz JJ, Garcia-Palomo A, Arizcun A, Pujol E, Diz P, Martin G, Fonseca E, Sánchez P, Rodriguez C, del Barco E and López Y: Biweekly docetaxel and vinorelbine in anthracycline- resistant metastatic breast cancer. Am J Clin Oncol Cancer Clin Trials 26: 127-131, 2003.
46. Vassilomanolakis M, Koumakis G, Drufakou S, Aperis G, Demiri M, Barbounis V, Missitzis J and Efremidis AP: Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemother Pharmacol 51: 179-183, 2003.
47. Di Lorenzo G, Pizza C, Autorino R, DeLaurentiis M, Marano O, D'Alessio A, Cancello G, Altieri V, Tortora G, Perdona S, Bianco AR and De Placido S: Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. Eur Urol 46: 712-716, 2004.
48. Mayordomo JI, Millá A, Morales S, Yubero A, Lorenzo A, Baena JM, Modolell A, Sanz J, Illarramendi J, Garcia MJ, Machengs I, Burillo MA and Tres A: Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer. Clin Breast Cancer 5: 131-135, 2004. (Pubitemid 39029205)
49. Strathopoulos G, Veslemes M, Georgatou N, Antoniou D, Giamboudakis P, Katis K, Tsavdaridis D, Rigatos S, Dimitroulis I, Bastani S, Loukides S, Vergos K, Marossis K, Grigoratou T, Kalatzi E, Charalambatou M, Paspalli A, Michalopoulou P, Stoka M and Gerogianni A: Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small cell lung cancer: a randomized phase III trial. Ann Oncol 15: 1048-1055, 2004.
50. Govindan R, Lim W-T, Arquette MA, Goodner SA, Fears CL, Mortimer JE and Fracasso PM: A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Oncol Rep 15: 123-127, 2006.
51. Tester W, Ackler J, Tijani L and Leighton J: Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. Cancer J 12: 299-304, 2006.
52. Kuroki T, Drevon C, Saint Vincent L, Tomatis L and Montesano R: Studies on the use of liver parenchymal cells in in vitro carcinogenesis, Mecanisms d'Altération et de Réparation du DNA: Relations avec la Mutagenèse et la Cancérogénèse Chimique. Centre National de Recherche Scientifique, Paris, pp307-314, 1977.
53. Heckman CA: Cell shape and growth control. In: Advances in Cell Culture. Maramorosch K (ed). Academic Press, New York, pp85-156, 1985.
54. SAS Institute: SAS/STAT User's Guide. Version 6, 4th edition. SAS Institute, Inc., Cary, NC, 1989.
55. Vindelov LL, Christensen IJ and Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327, 1983.
56. Heckman CA, Urban JM, Cayer M, Li Y, Boudreau N, Barnes J, Plummer HK III, Hall C, Kozma R and Lim L: Novel p21- activated kinase-dependent protrusions characteristically formed at the edge of transformed cells. Exp Cell Res 295: 432-447, 2004.
57. Michelotti A, Gennari A, Salvadori B, Tognoni A, Tibaldi C, Baldini E and Conte PF: Paclitaxel and vinorelbine in anthracycline- pretreated breast cancer: a phase II study. Ann Oncol 7: 857-860, 1996. (Pubitemid 26345879)
58. Dieras V, Fumoleau P, Kalla S, Misset JL, Azli N and Pouillart P: Docetaxel in combination with doxirubicin or vinorelbine. Eur J Cancer 33 (suppl 7): S20-S22, 1997.
59. Tortoriello A, Facchini G, Caponigro F, Santangelo M, Benassai G, Persico G, Citarella A, Carola M, Marzano N and Iaffaioli RV: Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 47: 91-97, 1998.
60. Acuña LR, Langhi M, Pérez J, Acuña JR, Machiavelli M, Lacava J, Vallejo C, Romero A, Fasce H, Ortiz E, Grasso S, Amato S, Rodríguez R, Barbieri M and Leone B: Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 17: 74-81, 1999.
61. Bennouna J, Monnier A, Riviere A, Milleron B, Lemarie E, Trillet-Lenoir V, Soussan-Lazard K, Berille J and Douillard JY: A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer. Eur J Cancer 36: 1107-1112, 2000. (Pubitemid 30330908)
62. Martin M, Lluch A, Casado A, Carbonero IG, de Paz L, Esteban C, Insa A, Alfonso R, Garcia-Conde J and Diaz-Rubio E: Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure. Ann Oncol 11: 85-89, 2000.
63. Vici P, Amodio A, Di Lauro L, Conti F, Gionfra T, Belli F and Lopez M: First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer. Oncology 58: 3-7, 2000.
64. Breton JL, Westeel V, Jacoulet P, Mercier M, Chazard M and Depierre A: Phase I study of paclitaxel (Taxol®) plus vinorelbine (Navelbine®) in patients with untreated stage IIIb and IV nonsmall cell lung cancer. Lung Cancer 31: 295-301, 2001.
65. Brugnatelli S, Riccardi A, Danova M, Pugliese P, Tinelli C, Luchena G, Bernardo A, Giardina G, Fava S, Montanari G, Pedrotti C and Poli AM: Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: A phase II study. Oncol Rep 8: 801-805, 2001.
66. Perez JE, Machiavelli MR, Romero AO, Acuña LAR, Dominguez ME, Fasce H, Acosta LF, Marrone N, Acuna JMR, Langhi MJ, Amato S, Bologna F, Ortiz EH, Leone BA, Lacava JA and Vallejo CT: Vinorelbine and paclitaxel for locoregional advanced or metastatic non-small-cell lung cancer. Am J Clin Oncol Cancer Clin Trials 25: 383-387, 2002.
67. Ballestrero A, Montemurro F, Gonella R, Capaldi A, Danova M, Friedman D, Puglisi M, Aglietta M and Patrone F: Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: anti-tumor activity and peripheral blood progenitor cell mobilization capability. Breast Cancer Res Treat 82: 185-190, 2003.
68. Koletsky AJ, Guerra ML and Kronish L: Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer. Cancer J 9: 286-292, 2003.
69. Polyzos A, Tsavaris N, Kosmas C, Gogas H, Toufexi H, Kosmidis C, Markopoulos C, Giannopoulos A, Papadopoulos O, Stamatiadis D and Kouraklis G: Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: A phase II study. J Chemother 15: 607-612, 2003.
70. Cals L, Nouyrigat P, Valenza B, Pedinelli FJ and Juin P: Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: A phase I/II study. Oncology 67: 257-261, 2004.
71. Spano JP, Bouillet T, Boaziz C, Piperno-Neumann S, Brunel P, Hennebelle F, Amsalhem P, Brunet-Pommeyrol A, Kanoui A, Morin F, Breau JL and Morere JF: Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer. Am J Clin Oncol Cancer Clin Trials 27: 317-321, 2004.
72. Goodin S, Rao KV, Kane M, Dave N, Capanna T, Doyle-Lindrud S, Engle E, Jin LX, Todd M and DiPaola RS: A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemother Pharmacol 56: 199-204, 2005.
73. Grunberg SM, Dugan MC, Greenblatt MS, Ospina DJ and Valentine JW: Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancer. Cancer Invest 23: 392-398, 2005.
74. Page RD, Smith FP, Geils GF, Beall CL, Fridman M and Allen BJ: Dose-dense vinorelbine and docetaxel with filgrastim support in patients with advanced nonsmall cell lung carcinoma. Cancer 104: 1956-1961, 2005.
75. Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL and Sweeney CJ: Hoosier oncology group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormonerefractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 12: 6094-6099, 2006.
76. Limentani SA, Brufsky AM, Erban JK, Jahanzeb M and Lewis D: Phase II study of neoadjuvant docetaxel/vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer. Clin Breast Cancer 6: 511-517, 2006.
77. Savio G, Laudani A, Leonardi V, Pepe A, Scianna C, Gebbia V and Agostara B: Treatment of metastatic breast cancer with vinorelbine and docetaxel. Am J Clin Oncol Cancer Clin Trials 29: 276-280, 2006.
78. Socinski MA: Cytotoxic chemotherapy in advanced non-small cell lung cancer: A review of standard treatment paradigms. Clinical Cancer Res 10 (suppl): 4210-4214, 2004.
79. Knick VC, Eberwein D and Miller C: Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 87: 1072-1077, 1995.
80. Budman DR, Calabro A, Wang LG, Liu XM, Stiel L, Adams LM and Kreis W: Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. Cancer Invest 18: 695-701, 2000.
81. Kano Y, Akutsu M, Suzuki K, Ando J and Tsunoda S: Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro. Breast Cancer Res Treat 56: 77-90, 1999.
82. Aoe K, Kiura K, Ueoka H, Tabata M, Matsumura T, Chikamori M, Matsushita A, Kohara H and Harada M: Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res 19: 291-299, 1999. (Pubitemid 29168252)
83. Hesketh PJ, Chansky K, Lau DHM, Doroshow JH, Moinpour CM, Chapman RA, Goodwin JW, Gross HM, Crowley JJ and Gandara DR: Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: A phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol 1: 537-544, 2006.
84. Edelman MJ, Gandara DR, Hausner P, Israel V, Thornton D, DeSanto J and Doyle LA: Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer 39: 197-199, 2003.
85. Butler MS: Natural products to drugs: natural product derived compounds in clinical trials. Nat Prod Rep 22: 162-195, 2005.
86. Ebbinghaus S, Rubin E, Hersh E, Cranmer LD, Bonate PL, Fram RJ, Jekunen A, Weitman S and Hammond LA: A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 11: 7807-7816, 2005. (Pubitemid 41611625)
87. Arif JM, Al-Hazzani AA, Kunhi M and Al-Khodairy F: Novel marine compounds: Anticancer or genotoxic? J Biomed Biotech 2: 93-98, 2004.
88. Yvon A-MC, Gross DJ and Wadsworth P: Antagonistic forces generated by myosin II and cytoplasmic dynein regulate microtubule turnover, movement, and organization in interphase cells. Proc Natl Acad Sci USA 98: 8656-8661, 2001.
89. Kaverina I, Krylyshkina O and Small JV: Regulation of substrate adhesion dynamics during cell motility. Int J Biochem Cell Biol 34: 746-761, 2002.
90. Jung M, Grunberg S, Timblin C, Buder-Hoffman S, Vacek P, Taatjes DJ and Mossman BT: Paclitaxel and vinorelbine cause synergistic increases in apoptosis but not in microtubular disruption in human lung adenocarcinoma cells (A-549). Histochem Cell Biol 121: 115-121, 2004.
91. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ and Pu YS: Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65: 8455-8460, 2005.